GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoString Technologies Inc (OTCPK:NSTGQ) » Definitions » Cash Conversion Cycle

NanoString Technologies (NanoString Technologies) Cash Conversion Cycle : 160.70 (As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is NanoString Technologies Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

NanoString Technologies's Days Sales Outstanding for the three months ended in Sep. 2023 was 86.65.
NanoString Technologies's Days Inventory for the three months ended in Sep. 2023 was 154.64.
NanoString Technologies's Days Payable for the three months ended in Sep. 2023 was 80.59.
Therefore, NanoString Technologies's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2023 was 160.70.


NanoString Technologies Cash Conversion Cycle Historical Data

The historical data trend for NanoString Technologies's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoString Technologies Cash Conversion Cycle Chart

NanoString Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 165.98 122.74 185.14 182.71 224.98

NanoString Technologies Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 270.70 197.98 190.07 163.55 160.70

Competitive Comparison of NanoString Technologies's Cash Conversion Cycle

For the Medical Instruments & Supplies subindustry, NanoString Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoString Technologies's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoString Technologies's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where NanoString Technologies's Cash Conversion Cycle falls into.



NanoString Technologies Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

NanoString Technologies's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=102.73+208.38-86.13
=224.98

NanoString Technologies's Cash Conversion Cycle for the quarter that ended in Sep. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=86.65+154.64-80.59
=160.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NanoString Technologies  (OTCPK:NSTGQ) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


NanoString Technologies Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of NanoString Technologies's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoString Technologies (NanoString Technologies) Business Description

Traded in Other Exchanges
Address
530 Fairview Avenue North, Seattle, WA, USA, 98109
NanoString Technologies Inc is engaged in the development, manufacturing and commercialization of instruments, consumables, and services for efficiently profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its core technology includes proprietary chemistries that enable the labeling and counting of single molecules. The firm uses its technology to develop tools for scientific and clinical research, primarily in the fields of genomics and proteomics. It offers two product platforms such as nCounter Analysis System or nCounter, and GeoMx Digital Spatial Profiler or DSP system both include instruments, related consumables, and software. NanoString Technologies generates revenue from the sale of products and related services and collaborations.
Executives
Jonathan Todd Garland officer: Chief Commercial Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
K Thomas Bailey officer: Chief Financial Officer 1618 STATION STREET, VANCOUVER A1 V6A 1B6
R Bradley Gray director, officer: President and CEO 530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
William Young director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waite Charles P Jr director, 10 percent owner 11023 NE 116TH STREET, KIRKLAND WA 98034
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Teresa M. Foy director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Joseph M Beechem officer: SVP, Research & Development 530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
John D. Gerace officer: Chief Commercial Officer C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
J. Chad Brown officer: SVP, Sales & Marketing 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Janet George director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Dana E. Rollison director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109